CN112672759A - 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途 - Google Patents
抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途 Download PDFInfo
- Publication number
- CN112672759A CN112672759A CN201980059111.0A CN201980059111A CN112672759A CN 112672759 A CN112672759 A CN 112672759A CN 201980059111 A CN201980059111 A CN 201980059111A CN 112672759 A CN112672759 A CN 112672759A
- Authority
- CN
- China
- Prior art keywords
- antibody
- antigen
- binding portion
- seq
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
本发明提供了抗程序性死亡配体‑1(PD‑L1)抗体用于制备治疗肿瘤(例如淋巴瘤或实体瘤)药物的用途。
Description
PCT国内申请，说明书已公开。
Claims (20)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811144919 | 2018-09-29 | ||
| CN2018111449192 | 2018-09-29 | ||
| PCT/CN2019/106599 WO2020063433A1 (zh) | 2018-09-29 | 2019-09-19 | 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112672759A true CN112672759A (zh) | 2021-04-16 |
| CN112672759B CN112672759B (zh) | 2023-05-30 |
Family
ID=69953360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980059111.0A Active CN112672759B (zh) | 2018-09-29 | 2019-09-19 | 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN112672759B (zh) |
| WO (1) | WO2020063433A1 (zh) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ590308A (en) * | 2005-06-08 | 2012-02-24 | Dana Farber Cancer Inst Inc | Methods and compositions for the treatment of cancer by inhibiting the programmed cell death 1 (pd-1) pathway |
| WO2017148424A1 (zh) * | 2016-03-04 | 2017-09-08 | 四川科伦博泰生物医药股份有限公司 | 一种pdl-1抗体、其药物组合物及其用途 |
| CN107496933A (zh) * | 2017-08-21 | 2017-12-22 | 山东新华制药股份有限公司 | 一种用于治疗胰腺癌的抗体药物偶联物及其制备方法 |
| US20180113131A1 (en) * | 2015-04-30 | 2018-04-26 | Kyoto University | Method of predicting effect of treatment by pd-1/pd-l1 blockade using abnormality of pd-l1 (cd274) as index |
-
2019
- 2019-09-19 CN CN201980059111.0A patent/CN112672759B/zh active Active
- 2019-09-19 WO PCT/CN2019/106599 patent/WO2020063433A1/zh active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ590308A (en) * | 2005-06-08 | 2012-02-24 | Dana Farber Cancer Inst Inc | Methods and compositions for the treatment of cancer by inhibiting the programmed cell death 1 (pd-1) pathway |
| US20180113131A1 (en) * | 2015-04-30 | 2018-04-26 | Kyoto University | Method of predicting effect of treatment by pd-1/pd-l1 blockade using abnormality of pd-l1 (cd274) as index |
| WO2017148424A1 (zh) * | 2016-03-04 | 2017-09-08 | 四川科伦博泰生物医药股份有限公司 | 一种pdl-1抗体、其药物组合物及其用途 |
| CN107151269A (zh) * | 2016-03-04 | 2017-09-12 | 四川科伦博泰生物医药股份有限公司 | 一种pdl‑1抗体、其药物组合物及其用途 |
| CN107496933A (zh) * | 2017-08-21 | 2017-12-22 | 山东新华制药股份有限公司 | 一种用于治疗胰腺癌的抗体药物偶联物及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| PAULINE GRAVELLE等: "Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies", 《ONCOTARGET》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112672759B (zh) | 2023-05-30 |
| WO2020063433A1 (zh) | 2020-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7234142B2 (ja) | Ｆｌｔ３に特異的な抗体およびその使用 | |
| EP3334431B1 (en) | 5-bromo-2,6-di-(1h-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| KR20190074300A (ko) | 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약 | |
| KR20180103150A (ko) | 암을 치료하기 위한 ox40 작용제 및 4-1bb 작용제 단클론 항체의 조합 | |
| CN111196852A (zh) | 抗tigit抗体及其用途 | |
| KR20180097615A (ko) | Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법 | |
| CN111936519A (zh) | 对cd70具有特异性的抗体及其用途 | |
| JP7274426B2 (ja) | 抗ｇｉｔｒアゴニスト抗体での癌の処置 | |
| CA3145940A1 (en) | Anti-cd39 antibody compositions and methods | |
| WO2020007368A1 (zh) | 低adcc/cdc功能性单抗及其制备方法与应用 | |
| JP2021535758A (ja) | 二重特異性抗原結合タンパク質及びその使用 | |
| CN112566937A (zh) | 对cd3特异性的抗体及其用途 | |
| JP2023502091A (ja) | 免疫療法のための組成物及び方法 | |
| JP2019031552A (ja) | Ｐｄ−１系結合アンタゴニストおよび抗ｇｐｃ３抗体を使用して癌を治療する方法 | |
| JP2022553129A (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| WO2020135335A1 (en) | Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof | |
| AU2021308586A1 (en) | Therapeutic antibodies and their uses | |
| WO2021146191A1 (en) | Method of treating a tumor with a combination of il-7 protein and a bispecific antibody | |
| CN111973739A (zh) | 抗pd-l1单克隆抗体治疗癌症的用途 | |
| CN113811329A (zh) | 抗pd-1抗体和其用途 | |
| WO2021129775A1 (zh) | 抗ctla-4单克隆抗体及其制备方法与应用 | |
| CN112672759B (zh) | 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途 | |
| WO2023227115A1 (en) | A method of treating solid tumor | |
| US20240117030A1 (en) | Multispecific antibodies and uses thereof | |
| WO2024044675A1 (en) | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |